文献速递胸部肿瘤

吉非替尼对比顺铂联合长春瑞滨用于EGFR突变II-IIIA期非小细胞肺癌完全切除术后患者的随机III期研究(IMPACT)

Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non-Small-Cell Lung Cancer With EGFR Mutation (IMPACT).
PubMed 文献 · J Clin Oncol · 2021-11-02

IMPACT研究为随机、开放标签III期试验,纳入完全切除的病理II-III期伴EGFR突变(19外显子缺失或L858R)非小细胞肺癌患者,随机接受吉非替尼250 mg每日一次共24个月或顺铂联合长春瑞滨四周期辅助治疗。234例随机分组,232例可评估,吉非替尼组与顺铂联合长春瑞滨组中位无病生存期分别为35.9个月和25.1个月,但差异无统计学意义(分层log-rank P=0.63;HR=0.92;95%CI 0.67-1.28),总生存亦无差异。

要点

  • 吉非替尼组与顺铂联合长春瑞滨组中位无病生存期分别为35.9个月和25.1个月,差异无统计学意义(P=0.63;HR=0.92;95%CI 0.67-1.28)。
  • 两组总生存无差异(P=0.89;HR=1.03;95%CI 0.65-1.65),5年总生存率分别为78.0%和74.6%。
  • 治疗相关死亡在吉非替尼组为0例,在顺铂联合长春瑞滨组为3例。

核心结论

  • 辅助吉非替尼似乎可预防早期复发,但未延长无病生存期或总生存期。
  • 相似的无病生存和总生存可能支持在特定患者亚组(尤其被认为不适合铂类双药辅助治疗者)中使用辅助吉非替尼,但该研究并非非劣效性试验。

研究设计与样本

  • IMPACT(WJOG6410L;UMIN000006252)为随机、开放标签、III期研究,纳入2011年9月至2015年12月完全切除的病理II-III期伴EGFR突变(19外显子缺失或L858R)非小细胞肺癌患者。
  • 患者随机接受吉非替尼250 mg每日一次共24个月,或顺铂80 mg/m2第1天联合长春瑞滨25 mg/m2第1天和第8天,每3周一次共四周期。
  • 共234例患者随机分组,232例符合条件纳入分析(每组116例;排除2例撤回知情同意者)。
  • 主要终点为无病生存期。

主要发现

  • 吉非替尼组与顺铂联合长春瑞滨组中位无病生存期分别为35.9个月和25.1个月,但Kaplan-Meier曲线在术后约4年交叉,差异无统计学意义(分层log-rank P=0.63;分层Cox比例风险模型HR=0.92;95%CI 0.67-1.28)。
  • 总生存亦无差异(分层log-rank P=0.89;HR=1.03;95%CI 0.65-1.65),吉非替尼组与顺铂联合长春瑞滨组5年总生存率分别为78.0%和74.6%。
  • 治疗相关死亡在吉非替尼组为0例,在顺铂联合长春瑞滨组为3例。

临床怎么用

  • 作者认为,相似的无病生存和总生存可能支持在特定患者亚组(尤其被认为不适合铂类双药辅助治疗者)中使用辅助吉非替尼,但该研究并非非劣效性试验。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate the efficacy of gefitinib as an adjuvant therapy for non-small-cell lung cancer patients with EGFR mutation. PATIENTS AND METHODS: IMPACT (WJOG6410L; University Hospital Medical Information Network Clinical Trials Registry: UMIN000006252), a randomized, open-label, phase III study, included patients with completely resected pathologic stage II-III non-small-cell lung cancer harboring EGFR mutations (exon 19 deletion or L858R) during September 2011 to December 2015. Patients were randomly assigned to receive gefitinib (250 mg once daily) for 24 months or cisplatin (80 mg/m2 on day 1) plus vinorelbine (25 mg/m2 on days 1 and 8; cis/vin) once every 3 weeks for four cycles. The primary end point was disease-free survival (DFS). RESULTS: Overall, 234 patients were randomly assigned. Among 232 eligible patients (116 each; excluding two who withdrew consent), the median DFS was 35.9 and 25.1 months in the gefitinib and cis/vin groups, respectively. However, Kaplan-Meier curves crossed around 4 years after surgery with no statistically significant difference (stratified log-rank P = .63; hazard ratio by stratified Cox proportional hazards model = 0.92; 95% CI, 0.67 to 1.28). Overall survival (OS) was also not different (stratified log-rank P = .89; hazard ratio = 1.03; 95% CI, 0.65 to 1.65), with the 5-year OS rates being 78.0% and 74.6% in the gefitinib and cis/vin groups, respectively. Treatment-related deaths occurred in 0 and three patients in the gefitinib and cis/vin groups, respectively. CONCLUSION: Although adjuvant gefitinib appeared to prevent early relapse, it did not prolong DFS or OS. However, similar DFS and OS may justify adjuvant gefitinib in the selected patient subsets, especially those deemed ineligible for platinum-doublet adjuvant therapy; however, this was not a noninferiority trial.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Tada H, Mitsudomi T, Misumi T, et al. Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non-Small-Cell Lung Cancer With EGFR Mutation (IMPACT). J Clin Oncol. 2021. PMID: 34726958. doi:10.1200/JCO.21.01729

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。